Floatz logo

Encorafenib

Metastatic Colon Adenocarcinoma

Fondazione Policlinico Universitario Agostino Gemelli IRCCSSmall moleculePhase 2/3Active
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

46 Active assets in the Metastatic Colon Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Eloxatin
Sun Yat-sen University
Phase 3BBB
FLUOROURACILUM
Merck Sharp & Dohme LLC
Phase 3BBB
Irinotecan
Sun Yat-sen University
Phase 3BBB
Eloxatin
Merck Sharp & Dohme LLC
Phase 3BBB
Irinotecan
SWOG Cancer Research Network
Phase 3BBB

View all 50 →

Same molecule, other indications

Encorafenib is also rated in:

colon carcinomaDormant
BB
Indicative ·
68 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
64 / 100
View asset →
metastatic melanomaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →